Fennec Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Fennec Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Fennec Pharmaceuticals Inc
Rating: 0.744583375
Author: Trendlyne DVM scores

Momentum Trap

about

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The comp...

6.93 0.03 (0.43%)

30.14% Fall from 52W High

210.6K

XNAS Volume

XNAS 08 May, 2026 4:01 PM (EDT)

Board Meeting

The next board meeting for Fennec Pharma Inc is on 13 May 2026 for the purpose of Fennec Pharmaceuticals Inc First Quarter Earnings Results for 2026 See details

Low Financial Strength

0.0 / 100

Expensive Valuation

13.7 / 100

Technically Neutral

45.9 / 100

Momentum Trap These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 119%

6 analysts

Fennec Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Fennec Pharma Inc Live Stock Price Today, Share Analysis and Chart

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The comp...

30.14% Fall from 52W High

SWOT Analysis

Fennec Pharma Inc Live Price Chart